Carfilzomib (PR-171)

For research use only.

Catalog No.S2853

147 publications

Carfilzomib (PR-171) Chemical Structure

CAS No. 868540-17-4

Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities. Carfilzomib activates prosurvival autophagy and induces cell apoptosis.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 476 In stock
USD 170 In stock
USD 270 In stock
USD 670 In stock
USD 870 In stock
USD 1170 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Carfilzomib (PR-171) has been cited by 147 publications

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities. Carfilzomib activates prosurvival autophagy and induces cell apoptosis.
Targets
Proteasome [1]
(ANBL-6 cells)
5 nM
In vitro

Carfilzomib inhibits proliferation in a variety of cell lines and patient-derived neoplastic cells, including multiple myeloma, and induced intrinsic and extrinsic apoptotic signaling pathways and activation of c-Jun-N-terminal kinase (JNK). Carfilzomib reveals enhanced anti-MM activity compared with bortezomib, overcome resistance to bortezomib and other agents, and acts synergistically with dexamethasone (Dex). Carfilzomib shoes preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, with over 80% inhibition at doses of 10 nM. Short exposure to low-dose Carfilzomib leads to preferential binding specificity for the β5 constitutive 20S proteasome and the β5i immunoproteasome subunits. Measurement of caspase activity in ANBL-6 cells pulsed with Carfilzomib reveals substantial increases in caspase-8, caspase-9, and caspase-3 activity after 8 hours, giving a 3.2-, 3.9- and 6.9-fold increase, respectively, over control cells after 8 hours. In carfilzomib pulse-treated cells, the mitochondrial membrane integrity is decreased to 41% (Q1 + Q2), compared with 75% in vehicle-treated control cells. [1] In another study, Carfilzomib has also shown preclinical effectiveness against hematological and solid malignancies. [2] Carfilzomib directly inhibits osteoclasts formation and bone resorption. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MM.1S NEDpOo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoWxNE0yODBibl2= NX;pZXZiPDhiaB?= NHW1WYlKSzVywrC9xsAyOCCwTR?= M37yVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{GyOVQ{Lz5{NUOxNlU1OzxxYU6=
NCI-H929  M4SzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfJ[2xtOC1zMECgcm0> NFPqO4o1QCCq M4TKcWlEPTBiPdMgNVQhdk1? M3vCZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{GyOVQ{Lz5{NUOxNlU1OzxxYU6=
SUDHL16  NInpVGdCeG:ydH;zbZMhSXO|c3H5 NYXj[VdCOi534pETN{42KG6P MnfqOFghcA>? MoDa[Y5p[W6lZYOgeIhmKGOnbHyg[IVifGhiY3:teJJm[XSvZX70JJdqfGhiQVPZNVIyPQ>? MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ|OUmzOUc,OjV{M{m5N|U9N2F-
SUDHL14 MlHwRZBweHSxc3nzJGF{e3OjeR?= MYCyMlXjiJN|LkWgcm0> NXvGRWd1PDhiaB?= MUPlcohidmOnczD0bIUh[2WubDDk[YF1cCClbz30doVifG2nboSge4l1cCCDQ2mxNlE2 M{HOXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkO5PVM2Lz5{NUKzPVk{PTxxYU6=
U2932 MWLBdI9xfG:|aYOgRZN{e2G7 MkHiNk426oDVMz61JI5O M3m1eVQ5KGh? M4P3NIVvcGGwY3XzJJRp\SClZXzsJIRm[XSqIHPvMZRz\WG2bXXueEB4cXSqIFHDXVEzOTV? NFrkdVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKzPVk{PSd-MkWyN|k6OzV:L3G+
P-UMSCC-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1S2fWlEPTB;MUGuNkBvVQ>? NIDyUnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxOVA{QSd-MkS5NVUxOzl:L3G+
R-UMSCC-1 M3;3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDtdWc5UUN3ME2yNlk1KG6P NInvNmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxOVA{QSd-MkS5NVUxOzl:L3G+
P-Cal33 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTF5LkOgcm0> M1fMTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUG1NFM6Lz5{NEmxOVA{QTxxYU6=
R-Cal33 MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPHTWM2OD1zMUGyJI5O NX:xWnJ7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUxOzlpPkK0PVE2ODN7PD;hQi=>
Jurkat MnO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE[3PFQyNTFzbl2= NGr2d3c1QCCq MoXabY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiClbz30doVifG2nboSge4l1cCC4b4Lpco9{fGG2 NGLFcZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEiwNVEzQCd-MkS4NFEyOjh:L3G+
Jurkat NEPyOW9CeG:ydH;zbZMhSXO|c3H5 MWW4JI5O M2H6PFI1NzR6IHi= MknRbY5lfWOnczDhdI9xfG:|aYOsJINie3Cjc3WgZYN1cX[jdHnvckwh[W6mIGDBVnAh[2ynYY\h[4Uh[29vdILlZZRu\W62IIfpeIghfm:{aX7vd5RifA>? NWToXo9mRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NFEyOjhpPkK0PFAyOTJ6PD;hQi=>
UMSCC-22A NUCxU|hsSXCxcITvd4l{KEG|c4PhfS=> NVvCNZVoOjByIH7N M1;w[|I1KGh? NHfV[JpqdmS3Y3WgeIhmKGOnbHygZZBweHSxc3nzJINwNXS{ZXH0cYVvfCC5aYToJG9PYCByOUGy Ml;jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7Mkm4NFMoRjJ{OUK5PFA{RC:jPh?=
UMSCC-22B NEK3WHZCeG:ydH;zbZMhSXO|c3H5 NUXS[3FQOjByIH7N NXfT[FQ6OjRiaB?= M3K0T4lv\HWlZTD0bIUh[2WubDDhdI9xfG:|aYOgZ48ufHKnYYTt[Y51KHerdHigU25ZKDB7MUK= MoW2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7Mkm4NFMoRjJ{OUK5PFA{RC:jPh?=
1483 NUf6bFhsSXCxcITvd4l{KEG|c4PhfS=> NWnxd4xlOjByIH7N NXH1d3lWOjRiaB?= MXLpcoR2[2VidHjlJINmdGxiYYDvdJRwe2m|IHPvMZRz\WG2bXXueEB4cXSqIF;OXEAxQTF{ MmLhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7Mkm4NFMoRjJ{OUK5PFA{RC:jPh?=
UMSCC-1 NUPUe3VZSXCxcITvd4l{KEG|c4PhfS=> NIq2NVIzODBibl2= NVHDfnlQOjRiaB?= MU\pcoR2[2VidHjlJINmdGxiYYDvdJRwe2m|IHPvMZRz\WG2bXXueEB4cXSqIF;OXEAxQTF{ NF7oRWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkmyPVgxOyd-MkK5Nlk5ODN:L3G+
UMSCC-22A Mkm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLqTWM2OD1|OD63JOKyKDFwMDDuUS=> NWHzSVlXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5Nlk5ODNpPkKyPVI6QDB|PD;hQi=>
UMSCC-22B NX\3dVZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHZU2NbUUN3ME2zNE44KMLzIEmuN{BvVQ>? NYPzcplWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5Nlk5ODNpPkKyPVI6QDB|PD;hQi=>
1483 M1vyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHhbY1KSzVyPUWwMlUhyrFiMUGuPUBvVQ>? MkXuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7Mkm4NFMoRjJ{OUK5PFA{RC:jPh?=
UMSCC-1 NXHabYJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTN2Lk[gxtEhOi54IH7N NGjKd5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkmyPVgxOyd-MkK5Nlk5ODN:L3G+
Cal33 NVXZbFdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nzSmlEPTB;NEmuN{DDuSB6Lkmgcm0> MoK5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7Mkm4NFMoRjJ{OUK5PFA{RC:jPh?=
PCI-15A NGOybphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvDUlFWUUN3ME23NE41KMLzIEKyMlYhdk1? M4XKclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUK5PFA{Lz5{MkmyPVgxOzxxYU6=
PCI-15B NFzndm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV2zfXAxUUN3ME2zPU42KMLzIEGxMlAhdk1? MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl{OUiwN{c,OjJ7Mkm4NFM9N2F-
OSC-19 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnOTWM2OD1zOD6zJOKyKDRwMjDuUS=> MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl{OUiwN{c,OjJ7Mkm4NFM9N2F-
SUDHL16 MXzBdI9xfG:|aYOgRZN{e2G7 MXKyMlAuPC5yIH7N M4TTdFQ5KGh? MUnpcoR2[2W|IHPlcIwh\GWjdHigZ48ufHKnYYTt[Y51KHerdHigc4JifG:lbHH4 M1nHOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEGxPFk6Lz5{MkSxNVg6QTxxYU6=
SUDHL16 MlrZSpVv[3Srb36gRZN{[Xl? MoHBNk42KG6P MknONlQhcA>? MkDlZYN1cX[jdHXzJGpPUyxiaX7hZ5RqfmG2ZYOgRWtVNCC3cD3y[Yd2dGG2ZYOgUo95[SxiYX7kJIlv\HWlZYOg{tNJOkFwWDDjc{11emWjdH3lcpQhf2m2aDDvZoF1d2OuYYi= M1T0PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEGxPFk6Lz5{MkSxNVg6QTxxYU6=
Granta Mln5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLldHF4OC12IH7N MUK0PEBp M{TNWYlv\HWlZTDj[YxtKGSnYYToJINwNXS{ZXH0cYVvfCC5aYToJGhCTEOLcx?= NWPuS|B4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3OVAzOjRpPkKxO|UxOjJ2PD;hQi=>
SUDHL16 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXKxMVQhdk1? NEfaWZA{PiCq NX;iT4hzcW6mdXPlJINmdGxiZHXheIgh[29vdILlZZRu\W62IIfpeIghUEGGQ1nz M{X4WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMkOzPVc{Lz5{MEKzN|k4OzxxYU6=
MOLT4 NIDWe2tHfW6ldHnvckBie3OjeR?= MXGxJIhz NFn6SZRKdmirYnn0bY9vKG:oIHPofY1wfHK7cIPpck1tcWunIHHjeIl3cXS7IH;mJFIxWyCycn;0[YF{d22nIHnuJIh2dWGwIF3PUHQ1KGOnbHzzJIFnfGW{IEGgbJIh[nliQ3XscHRqfGW{LVfsc{BtfW2rbnXzZ4VvfCCjc4PhfUwhUUN3MDC9JFAvODB3MTFOwG0v M4HlNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7M{S4OFc{Lz5zOUO0PFQ4OzxxYU6=
MESSA NHHOR2VEgXSxdH;4bYNqfHliYYPzZZk> NGnISFI4OiCqcoO= MkTER5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWVUW0FiY3XscJMh[XO|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgO|IhcHK|IHL5JGNmdGyWaYTldk1IdG9ibIXtbY5me2OnboSgZZN{[XluIFnDOVAhRSByLkCxPEDPxE1w NEL1R|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUO0PFQ4Oyd-MUmzOFg1PzN:L3G+
MESSA MkTWR5l1d3SxeHnjbZR6KGG|c3H5 MoPVO|IhcHK| MnPXR5l1d3SxeHnjbZR6KGGpYXnud5QhdXWudHnkdpVoKHKnc3nzeIFv[2VidILhcpNxd3K2ZYKg[ZhxemW|c3nu[{Bld3ixcoXibYNqdiC{ZYPpd5RidnRiaIXtZY4hVUWVU1GgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gcJVucW6nc3PlcpQh[XO|YYmsJGlEPTBiPTCwMlQyOyEQvF2u M3H6PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7M{S4OFc{Lz5zOUO0PFQ4OzxxYU6=
RPMI8226 MVjDfZRwfG:6aXPpeJkh[XO|YYm= Mn3DO|IhcHK| MlPOR5l1d3SxeHnjJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUmDNTVgzOjZiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VWyCjc4PhfUwhUUN3MDC9JFAvODF|MUmg{txONg>? MmnFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5Nke4NVgoRjJ2N{[3PFE5RC:jPh?=
NCI-H929 MUPDfZRwfG:6aXPpeJkh[XO|YYm= MkXQO|IhcHK| NVHITmNtS3m2b4TvfIlkKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUmNKNUh7MkmgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDBwMEKxN|Ih|ryPLh?= NXi2XlZURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3Olc5OThpPkK0O|Y4QDF6PD;hQi=>
CCRF-CEM NVHDc4hqSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= Mn;rO|IhcHK| Mly2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCFQ2LGMWNGVSClZXzsd{Bi\nSncjC3NkBpenNiYomgc5h6dHWlaX\ldolvKGy3bXnu[ZNk\W6lZTDhd5NigSxiSVO1NEA:KDBwMEC2NUDPxE1w NWj2VJRGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yN|EyPjJpPkK2NlMyOTZ{PD;hQi=>
RPMI8266 MlX2RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M2LSSFczKGi{cx?= NU\ac21vSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDSVG1KQDJ4NjDj[YxteyCjZoTldkA4OiCqcoOgZpkhd3i7bIXjbYZmemmwIHz1cYlv\XOlZX7j[UBie3OjeTygTWM2OCB;IECuNFE{QSEQvF2u NH\lfGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkKzNVE3Oid-Mk[yN|EyPjJ:L3G+
HCT116 M1HoemFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MmLDO|IhcHK| NXK1XIw6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JI95gWy3Y3nm[ZJqdiCudX3pcoV{[2WwY3WgZZN{[XluIFnDOVAhRSByLkCxPVMh|ryPLh?= NXfBcGNpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yN|EyPjJpPkK2NlMyOTZ{PD;hQi=>
A431 MnniRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NYPvUXlrPzJiaILz NYn2XoFRSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOFMyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDvfJltfWOrZnXybY4hdHWvaX7ld4NmdmOnIHHzd4F6NCCLQ{WwJF0hOC5yMkO4JO69VS5? NFvhXnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkKzNVE3Oid-Mk[yN|EyPjJ:L3G+
TOV21G MXrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NGToZYo4OiCqcoO= NH\Fb|JCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGTPWlIyTyClZXzsd{Bi\nSncjC3NkBpenNiYomgc5h6dHWlaX\ldolvKGy3bXnu[ZNk\W6lZTDhd5NigSxiSVO1NEA:KDBwMEKzPEDPxE1w MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ|MUG2Nkc,OjZ{M{GxOlI9N2F-
RKO MmXkRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MUS3NkBpenN? NH:0NGJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGLLU{Bk\WyuczDh[pRmeiB5MjDodpMh[nlib4j5cJVkcW[ncnnuJIx2dWmwZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFAvODJ5MTFOwG0v NX[0[283RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yN|EyPjJpPkK2NlMyOTZ{PD;hQi=>
MM1S MVjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M161N|czKGi{cx?= MVnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2PMWOgZ4VtdHNibXXhd5Vz\WRiYX\0[ZIhPzJiaILzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDBwMECxOUDPxE1w Mn3QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5NkW0NFgoRjJ5N{[1OFA5RC:jPh?=
RPMI8226 MWTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NWrrN4hvPzJiaILz MmnGRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCUUF3JPFIzPiClZXzsd{Bu\WG|dYLl[EBi\nSncjC3NkBpenNiYomgUXRUKGG|c3H5MEBKSzVyIE2gNE4xOTN{IN88UU4> Ml;ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5NkW0NFgoRjJ5N{[1OFA5RC:jPh?=
LCL MlHqR5l1d3SxeHnjbZR6KGG|c3H5 NEnSbHA1QCCqcoO= M2qwfmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxEVCClZXzsd{Bp[XKkb4Lpcochf2muZDD0fZBmKHB3MzDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK|IHL5JFdCSURvc4ThbY5qdmdiYnHz[YQhTkGFUzDhcoFtgXOrczygUGQ2OCB;IECuNFMh|ryPLh?= M3PmOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUm0O|M1Lz5{N{m5OFc{PDxxYU6=
RD-ES M2jHOWN6fG:2b4jpZ4l1gSCjc4PhfS=> MV:0PEBpenN? NVzQfYRUS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWkRvRWOgZ4VtdHNiaHHyZo9zcW6pIIC1N{BufXSjboSgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUA4SUGGLYP0ZYlvcW6pIHLhd4VlKE[DQ2OgZY5idHm|aYOsJGxFPTBiPTCwMlA1OyEQvF2u MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl7NEezOEc,Ojd7OUS3N|Q9N2F-
U266 NGjSc4pEgXSxdH;4bYNqfHliYYPzZZk> MWO0PEBpenN? M1KybmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHUzPjZiY3XscJMhcGG{Yn;ybY5oKG23dHHueEBxPTNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCkeTC3RWFFNXO2YXnubY5oKGKjc3XkJGZCS1NiYX7hcJl{cXNuIFzEOVAhRSByLkC2JO69VS5? NIXNb5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m5OFc{PCd-Mke5PVQ4OzR:L3G+
WE68 NWnxWVhGS3m2b4TvfIlkcXS7IHHzd4F6 MYq0PEBpenN? MlTyR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gW2U3QCClZXzsd{Bp[XKkb4Lpcochf2muZDD0fZBmKHB3MzDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK|IHL5JFdCSURvc4ThbY5qdmdiYnHz[YQhTkGFUzDhcoFtgXOrczygUGQ2OCB;IECuNFgh|ryPLh?= M1\4UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUm0O|M1Lz5{N{m5OFc{PDxxYU6=
IMR90 NIK5TppEgXSxdH;4bYNqfHliYYPzZZk> M2[3d|Q5KGi{cx?= M3nLU2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGlOWjlyIHPlcIx{KGijcnLvdolv\yC5aXzkJJR6eGVicEWzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkhP0GDRD3zeIFqdmmwZzDiZZNm\CCIQVPTJIFv[Wy7c3nzMEBNTDVyIE2gNE4yOyEQvF2u NH7Hc5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m5OFc{PCd-Mke5PVQ4OzR:L3G+
MCF10A MmDzR5l1d3SxeHnjbZR6KGG|c3H5 MlHUOFghcHK| M1\CemN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjFyQTDj[YxteyCqYYLic5Jqdmdid3ns[EB1gXCnIIC1N{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPDhiaILzJIJ6KDeDQVStd5RicW6rbnegZoF{\WRiRlHDV{BidmGueYPpd{whVER3MDC9JFAvOzJizszNMi=> NH\Dc2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m5OFc{PCd-Mke5PVQ4OzR:L3G+
SKOV3 MV3DfZRwfG:6aXPpeJkh[XO|YYm= MYW0PEBpenN? MnXKR5l1d3SxeHnjbZR6KGGpYXnud5QheDV|IHTl[olkcWWwdDDoeY1idiCVS1;WN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK|IHL5JFdCSURvc4ThbY5qdmdiYnHz[YQhTkGFUzDhcoFtgXOrczygUGQ2OCB;IECuN|Ih|ryPLh?= MkfsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OUS3N|QoRjJ5OUm0O|M1RC:jPh?=
MDA-MB-468 NGXPSIVEgXSxdH;4bYNqfHliYYPzZZk> MmfTOFghcHK| M2nLNGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj20Olgh[2WubIOgbIFz[m:{aX7nJI12fGGwdDDwOVMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDR6IHjyd{BjgSB5QVHEMZN1[WmwaX7nJIJie2WmIF\BR3Mh[W6jbInzbZMtKEyGNUCgQUAxNjN|IN88UU4> MlLkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OUS3N|QoRjJ5OUm0O|M1RC:jPh?=
HNDF MXnDfZRwfG:6aXPpeJkh[XO|YYm= MXm0PEBpenN? NGPJXGFEgXSxdH;4bYNqfHliYXfhbY5{fCCKTlTGJINmdGy|IHjhdoJwemmwZzD3bYxlKHS7cHWgdFU{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDh[pRmeiB2ODDodpMh[nliN1HBSE1{fGGrbnnu[{Bj[XOnZDDGRWNUKGGwYXz5d4l{NCCOREWwJF0hOC5|NTFOwG0v NIH4dI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m5OFc{PCd-Mke5PVQ4OzR:L3G+
KGN NVT3N3JUS3m2b4TvfIlkcXS7IHHzd4F6 NYLoXldOPDhiaILz NFHmcHJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMT05iY3XscJMhcGG{Yn;ybY5oKHerbHSgeJlx\SCyNUOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUA4SUGGLYP0ZYlvcW6pIHLhd4VlKE[DQ2OgZY5idHm|aYOsJGxFPTBiPTCwMlQ2KM7:TT6= MlGwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OUS3N|QoRjJ5OUm0O|M1RC:jPh?=
MCF7 NF\jbZpEgXSxdH;4bYNqfHliYYPzZZk> NVy3XlZbPDhiaILz MXPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIhiemKxcnnu[{B4cWymIIT5dIUheDV|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgO2FCTC2|dHHpcolv\yCkYYPl[EBHSUOVIHHuZYx6e2m|LDDMSFUxKD1iND61JO69VS5? Mo[xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OUS3N|QoRjJ5OUm0O|M1RC:jPh?=
MCF7 MVLGeY5kfGmxbjDhd5NigQ>? NUDzc29yOzVibl2= MYC0JIhzew>? NEPLcZpKdmirYnn0bY9vKG:oIEK2V{Bxem:2ZXHzc41mKGmwIHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKG:oIHjp[4ghdW:uZXP1cIFzKHenaXfoeEBxd2y7dXLpdZVqfGmwLXPvcop2\2G2ZXSgdJJwfGWrboOgZZQhOzVibl2gZYZ1\XJiNDDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz M{TIc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUm0O|M1Lz5{N{m5OFc{PDxxYU6=
MDA-MB-468 MVvGeY5kfGmxbjDhd5NigQ>? NIjDd5Q{PSCwTR?= MVS0JIhzew>? MVrJcohq[mm2aX;uJI9nKDJ4UzDwdo91\WG|b33lJIlvKGi3bXHuJG1FSS2PQj20Olgh[2WubIOgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIH;mJIhq\2hibX;s[YN2dGG{IIflbYdpfCCyb3z5eYJqeXWrdHnuMYNwdmq3Z3H0[YQheHKxdHXpcpMh[XRiM{Wgcm0h[W[2ZYKgOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ NV[1b25rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5PVQ4OzRpPkK3PVk1PzN2PD;hQi=>
MM1S NFvBZVJEgXSxdH;4bYNqfHliYYPzZZk> MUW3NkBpenN? MmDNR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUW0yWyClZXzsd{Bu\WG|dYLl[EBi\nSncjC3NkBpenNiYomgUXRUKGG|c3H5MEBKSzVyIE2gNE4xODF3IN88UU4> M{jlW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEK3OVMyLz5{OECyO|U{OTxxYU6=
RPMI8226 NXPTN|doS3m2b4TvfIlkcXS7IHHzd4F6 NEjQfGc4OiCqcoO= MVLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDSVG1KQDJ{NjDj[YxteyCvZXHzeZJm\CCjZoTldkA4OiCqcoOgZpkhVVSVIHHzd4F6NCCLQ{WwJF0hOC5yMUOyJO69VS5? MmC2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyMke1N|EoRjJ6MEK3OVMyRC:jPh?=
TC32 M2DLSJFJXFNiYYPzZZk> NWnYW3pJeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGTDN|Ih[2WubIO= NGfRfm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
U-2 OS M2X3[ZFJXFNiYYPzZZk> NGLFeYRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVT2yJG9UKGOnbHzz MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
A673 M3zqUZFJXFNiYYPzZZk> Mn;sdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN? M3iyVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY MYLxTHRUKGG|c3H5 MmPkdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN? M4\lTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2 NUDnNIxReUiWUzDhd5NigQ>? NWK3N5RZeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=> MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
BT-37 NYTrNGdveUiWUzDhd5NigQ>? M2Pa[ZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2zO{Bk\Wyucx?= NH3GVXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
RD M2f5UZFJXFNiYYPzZZk> NXnhc5YyeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLEJINmdGy| NEC4TnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-SH MYPxTHRUKGG|c3H5 MmDldWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO= NW\UOXYzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12 NYf4cWMyeUiWUzDhd5NigQ>? MmezdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUGyJINmdGy| NGf0blg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
MG 63 (6-TG R) MoW3dWhVWyCjc4PhfS=> NWnNNpVDeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz NVLVSohVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643 M13wZpFJXFNiYYPzZZk> NWfsbYVseUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=> MknNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
OHS-50 NIHDeG5yUFSVIHHzd4F6 M3j2NpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO= NEL6[5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-12 M3nhNJFJXFNiYYPzZZk> NHPjdpNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBDXC1zMjDj[Yxtew>? NXPIb|JZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5 MoT4dWhVWyCjc4PhfS=> NHSwVVVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBNSU5vNTDj[Yxtew>? NWn0d5RURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
fibroblast cells MXHxTHRUKGG|c3H5 M1HSTpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiClb370do9tKEiqIIfpcIQhfHmyZTDmbYJzd2KuYYP0JINmdGy| NWH3R5V7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1 NXHSb|dXeUiWUzDhd5NigQ>? M1fidpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG5DNUWEY{GgZ4VtdHN? NHPjU4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-SH Mk\EdWhVWyCjc4PhfS=> MYDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTT{1PNVOKIHPlcIx{ NV7wXZJwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41 NXvPd4g{eUiWUzDhd5NigQ>? NVn4W5lReUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoOFEh[2WubIO= NXfUfmZ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673 NFLsUndyUFSVIHHzd4F6 Moj3dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRVY4OyClZXzsd{k> NIT6VHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh30 Mo\ydWhVWyCjc4PhfS=> Mle0dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqM{CgZ4VtdHN? NXHS[HViRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37 NWjzO3BMeUiWUzDhd5NigQ>? MnvBdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRnQuOzdiY3XscJM> NEDKXGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
MG 63 (6-TG R) MWTxTHRUKGG|c3H5 M1S4fpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG1IKDZ|IDi2MXRIKFJrIHPlcIx{ NYLr[4VuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh30 M2\FNZFJXFNiYYPzZZk> MnXodWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog{OCClZXzsdy=> NYPxSJFERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
fibroblast cells NFn6VFZyUFSVIHHzd4F6 MorudWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgZ49vfHKxbDDIbEB4cWymIIT5dIUh\mmkcn;icIF{fCClZXzsdy=> M1XlO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50 MULxTHRUKGG|c3H5 NISwRppyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBQUFNvNUCgZ4VtdHN? M16wc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH MnHhdWhVWyCjc4PhfS=> NFTC[WpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCRcoToc4dwdmGuIEPEJJZq[WKrbHn0fUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO= NXXjZ2hqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Daoy M4fCW5FJXFNiYYPzZZk> NUD5cFRweUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiT4L0bI9od26jbDCzSEB3cWGkaXzpeJkhe2O{ZXXuJIZweiCGYX;5JINmdGy| M3HCNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
TC32 NYLacnd7eUiWUzDhd5NigQ>? NWrVUoZoeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiT4L0bI9od26jbDCzSEBk[XOyYYPlJJNkemWnbjDmc5IhXEN|MjDj[Yxtew>? NXPhSXdURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
TC32 MYjxTHRUKGG|c3H5 MWXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBQenSqb3fvcoFtKDOGII\pZYJqdGm2eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM> MofpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R) MUXxTHRUKGG|c3H5 MYHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBQenSqb3fvcoFtKDOGII\pZYJqdGm2eTDzZ5Jm\W5iZn;yJG1IKDZ|IDi2MXRIKFJrIHPlcIx{ M1vTflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2 MorodWhVWyCjc4PhfS=> NIDrV|RyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=> NXjEfGVYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC M4LLeZFJXFNiYYPzZZk> M2e5OpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz Mle4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1 NUXSZpRseUiWUzDhd5NigQ>? NGOxZmJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKtSWJkOSClZXzsdy=> MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
LAN-5 NWrtUlAyeUiWUzDhd5NigQ>? NG\YNJJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO= NEXMdXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh18 NG\JeGZyUFSVIHHzd4F6 MVTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>? MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC MYXxTHRUKGG|c3H5 MYLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTT{1PNU2FIHPlcIx{ NHy2fGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SJ-GBM2 NVmzRoZteUiWUzDhd5NigQ>? NF;TN2tyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUi2JQl2yJINmdGy| M1jVR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
TC32 MUjxTHRUKGG|c3H5 MlvldWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgWGM{OiClZXzsdy=> NI\QXoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh18 M{\0SZFJXFNiYYPzZZk> MULxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFE5KGOnbHzz NILmVpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Saos-2 NWDvbWE3eUiWUzDhd5NigQ>? M{HKbpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNid3NvMjDj[Yxtew>? NFnBbVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SJ-GBM2 NEO0[JFyUFSVIHHzd4F6 NYrXUXNbeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiT4L0bI9od26jbDCzSEB3cWGkaXzpeJkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz NFLYPIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
RD M2HDd5FJXFNiYYPzZZk> MXfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBQenSqb3fvcoFtKDOGII\pZYJqdGm2eTDzZ5Jm\W5iZn;yJHJFKGOnbHzz NUfVPIFERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
ANBL-6 NVv0OHpiTnWwY4Tpc44h[XO|YYm= Ml;OTY5pcWKrdHnvckBw\iB{MGOgdJJwfGWjc3;t[UBi[3Srdnn0fUBqdiCqdX3hckBCVkKOLU[gZ4VtdHNuIFnDOVAhRSByLkCxJO69VS5? NGfmdno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[1NlE1Oyd-Mkm2OVIyPDN:L3G+
MCF7 NEC1ToxEgXSxdH;4bYNqfHliYYPzZZk> M2GyXlQ5KGi{cx?= MVPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTCwMlAxPDFizszNMi=> NF31OI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEG2OVM1PCd-M{CxOlU{PDR:L3G+
MDA-MB-231 M3jhVWN6fG:2b4jpZ4l1gSCjc4PhfS=> NF\wRZE1QCCqcoO= NV\GXVBCS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gNE4xODR2IN88UU4> M{fCdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMU[1N|Q1Lz5|MEG2OVM1PDxxYU6=
RPMI8226 MVfDfZRwfG:6aXPpeJkh[XO|YYm= NGjCW2Q1QCCqcoO= NUPxfJJMS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWlCPSUiyNlYh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFA3PyEQvF2u NIDHcXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEG2OVM1PCd-M{CxOlU{PDR:L3G+

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pERK / ERK / pSTAT5 / STAT5 / pPI3K / PI3K; 

PubMed: 24590311     


Western blot analysis for activated (phosphorylated) ERK, Stat5 and PI3K signaling pathways following exposure to carfilzomib, total levels of ERK, Stat5 and PI3K were used as a loading control.

caspase-9 / caspase-8; 

PubMed: 24590311     


Western blot analysis for activated (cleaved) caspase-8 and caspase-9 following exposure to carfilzomib.

c-PARP / PARP / caspase-3; 

PubMed: 22929803     


UMSCC-22A, UMSCC-22B, 1483 and UMSCC-1 cells were treated for 24 hours with 0.1% DMSO, or 200 nmol/L carfilzomib or ONX 0912, followed by immunoblotting with anti-PARP, anti-caspase-3, or anti-β-actin. Shown are full-length PARP, cleaved PARP (c-PARP), and the cleaved, active subunits of caspase-3. Similar results were obtained in 3 independent experiments.

Bcl-2 / Bcl-Xl / Mcl-1 / Bik / Bim / Bax / Bak; 

PubMed: 22929803     


UMSCC-22A, UMSCC-22B, 1483 and UMSCC-1 cells were treated for 24 hours with 0.1% DMSO, or 100 nmol/L carfilzomib or ONX 0912, followed by immunoblotting for the indicated proteins. In the case of Bik immunoblotting, cells were treated with 200 nmol/L carfilzomib or ONX 0912 to more clearly demonstrate Bik upregulation in 1483 and UMSCC-1 cells. Blots shown are representative of 3 independent experiments. 

Atg5 / Atg12 / Beclin-1 / LC3-II; 

PubMed: 22929803     


HNSCC cells were treated for 24 hours with 100 nmol/L carfilzomib or ONX 0912, or with 0.1% DMSO. Immunoblots were probed for Beclin-1, Atg5/12 conjugate, LC3-II, or β-actin. Representative blots from 3 independent experiments are shown. 

Noxa / Bik / Puma / Mcl-1; 

PubMed: 25548100     


SW620 cells were treated with the indicated dosage for 48 h. Expression of Noxa, Bik and/or Puma, c-myc and Mcl-1 proteins was then analyzed by immunoblotting. Tubulin served as control for protein loading. 

EGFR / HER2 / ER alpha / p-Akt(Ser473) / Akt / p-ERK / ERK / p53; 

PubMed: 29069787     


T47D and MCF7 cells were cultured with the indicated carfilzomib concentrations for 32 or 36 hours, respectively. Western blots of protein lysates were probed with the indicated antibodies. β-actin served as loading control.

BDP1 / HER2(Tyr1248) / HER2(Tyr1221/Tyr1222) / PARP1 / caspase-7 / p53 Mut; 

PubMed: 29069787     


BT474 cells were cultured in the presence of the indicated carfilzomib concentrations for 32 hours. Western blots of protein lysates were probed with the indicated antibodies.

HLA class I; 

PubMed: 26323098     


Immunofluorescence analysis was performed to confirm the consequence that down-regulation of HLA class I was in a dose- and time-dependent manner.

24590311 22929803 25548100 29069787 26323098
Growth inhibition assay
Cell viability; 

PubMed: 27655642     


Cytotoxic effects of carfilzomib on breast cancer cells in MTT assays. Seven human breast cancer cell lines, MCF7, T-47D, MDA-MB-361, HCC1954, MDA-MB-468, MDA-MB-231, and BT-549 were treated with carfilzomib at 0, 0.001 μM, 0.01 μM, 0.05 μM, 0.1 μM, 1 μM, 10 μM, or 50 μM for 72 h, then subjected to MTT assays. The absorbance of each well was measured at 540 nm and plotted for the cell viability curve. IC50 values of carfilzomib in breast cancer cell lines were listed.

27655642
In vivo Carfilzomib moderately reduces tumor growth in an in vivo xenograft model. Carfilzomib effectively decreases multiple myeloma cell viability following continual or transient treatment mimicking. Carfilzomib increases trabecular bone volume, decreases bone resorption and enhances bone formation in non-tumor bearing mice. [3]

Protocol

Kinase Assay:[1]
- Collapse

Enzyme-linked immunosorbent assay for subunit profiling of carfilzomib:

ANBL-6 cells (2 × 106/well) are plated in 96-well plates and treated with Carfilzomib doses from 0.001 to 10 μM for 1 hour. Cells are then lysed (20 mM Tris-HCl, 0.5 mM EDTA), and cleared lysates are transferred to polymerase chain reaction (PCR) plates. A standard curve is generated using untreated ANBL-6 cell lysates starting at a concentration of 6 μg protein/μL. The active site probe [biotin-(CH2)4-Leu-Leu-Leu-epoxyketone; 20 μM] is added and incubated at room temperature for 1 hour. Cell lysates are then denatured by adding 1% sodium dodecyl sulfate (SDS) and heating to 100°C, followed by mixing with 20 μL per well streptavidin-sepharose high-performance beads in a 96-well multiscreen DV plate and incubated for 1 hour. These beads are then washed with enzyme-linked immunosorbent assay (ELISA) buffer (PBS, 1% bovine serum albumin, and 0.1% Tween-20), and incubated overnight at 4°C on a plate shaker with antibodies to proteasome subunits. Antibodies used included mouse monoclonal anti-β1, anti-β2, anti-β1i, and anti-β5i, goat polyclonal anti-β2i, and rabbit polyclonal anti-β5 (affinity-purified antiserum against KLH-CWIRVSSDNVADLHDKYS peptide). The beads are washed and incubated for 2 hours with horseradish peroxidase-conjugated secondary goat antirabbit, goat antimouse or rabbit antigoat antibodies. After washing, the beads are developed using the supersignal ELISA picochemiluminescence substrate. Luminescent detection is performed. Raw luminescence is converted to μg/mL by comparison with the standard curve and expressed as the % inhibition relative to vehicle control. Curve fits are generated using the following nonsigmoidal dose-response equation: Y = Bottom + (Top-Bottom)/(1 + 10̂((LogEC50 − X) × HillSlope)), where X is the logarithm of concentration, Y is the % inhibition, and EC50 is the dose showing 50% effect.
Cell Research:[1]
- Collapse
  • Cell lines: WST-1, ANBL-6 cells
  • Concentrations: 100 nM
  • Incubation Time: 1 hour
  • Method: WST-1 is used to determine the effects of proteasome inhibitor Carfilzomib on cell proliferation. The inhibition of proliferation is calculated in relation to parallel control cells that receives vehicle alone. A linear spline function is used to interpolate the median inhibitory concentration (IC50) using XLfit 4 software. The degree of resistance (DOR) is calculated using the formula: DOR = IC50(resistant cells)/IC50(sensitive cells). ANBL-6 cells pulsed with 100 nM carfilzomib are washed and suspended in PBS containing 5 μg/mL of JC-1, which exhibits potential-dependent accumulation in mitochondria. Analysis of the mitochondrial membrane potential-dependent color shift from 525 to 590 nm is carried out on a FacScan, and the data are analyzed with CellQuest software.
    (Only for Reference)
Animal Research:[4]
- Collapse
  • Animal Models: Beige-nude-XID mice
  • Dosages: 2.0 mg/kg
  • Administration: i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 50 mg/mL (69.45 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+2%Tween 80+ddH2O
For best results, use promptly after mixing.
1mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 719.91
Formula

C40H57N5O7

CAS No. 868540-17-4
Storage powder
in solvent
Synonyms N/A
Smiles CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3)NC(=O)CN4CCOCC4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03512353 Terminated Drug: Dexamethasone|Drug: Carfilzomib Relapsed or Refractory Multiple Myeloma Amgen July 5 2018 Phase 2
NCT02412878 Completed Drug: Carfilzomib|Drug: Dexamethasone Multiple Myeloma Amgen September 9 2015 Phase 3
NCT02442648 Recruiting Drug: Carfilzomib|Drug: Rituximab Transplants and Implants E. Steve Woodle|Amgen|University of Cincinnati December 2014 Phase 1
NCT02257476 Completed Drug: Carfilzomib|Drug: Dexamethasone Neoplasms|Malignancies Emory University|Amgen August 2014 Phase 1
NCT01775553 Completed Drug: Carfilzomib Relapse Multiple Myeloma|Refractory Multiple Myeloma Ajai Chari|Amgen|Icahn School of Medicine at Mount Sinai September 2013 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How should I prepare solution of Carfilzomib for ongoing in vivo study?

  • Answer:

    This compound can be dissolved in 2% DMSO/30% PEG 300/dd H2O at 10 mg/ml as a suspension, and can be dissolved in 2% DMSO/ castor oil at 10 mg/ml as a clear solution.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products

Tags: buy Carfilzomib (PR-171) | Carfilzomib (PR-171) supplier | purchase Carfilzomib (PR-171) | Carfilzomib (PR-171) cost | Carfilzomib (PR-171) manufacturer | order Carfilzomib (PR-171) | Carfilzomib (PR-171) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID